{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.3","upperLimit":"20.2","value":"15.7"},{"groupId":"OG001","lowerLimit":"15.2","upperLimit":"20.9","value":"16.1"},{"groupId":"OG002","lowerLimit":"11.7","upperLimit":"20.6","value":"15.1"},{"groupId":"OG003","lowerLimit":"15.1","upperLimit":"35.7","value":"16.2"},{"groupId":"OG004","lowerLimit":"10.8","upperLimit":"26.2","value":"17.0"},{"groupId":"OG005","lowerLimit":"14.9","upperLimit":"20.1","value":"16.9"},{"groupId":"OG006","lowerLimit":"14.0","upperLimit":"26.2","value":"20.1"},{"groupId":"OG007","lowerLimit":"16.6","upperLimit":"16.6","value":"16.6"}]}],"title":"C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.0","upperLimit":"31.2","value":"20.8"},{"groupId":"OG001","lowerLimit":"19.8","upperLimit":"29.2","value":"24.5"},{"groupId":"OG002","lowerLimit":"14.9","upperLimit":"17.3","value":"15.7"},{"groupId":"OG003","lowerLimit":"16.5","upperLimit":"91.7","value":"22.2"},{"groupId":"OG004","lowerLimit":"5.18","upperLimit":"18.2","value":"14.4"},{"groupId":"OG005","lowerLimit":"11.3","upperLimit":"24.8","value":"18.4"},{"groupId":"OG006","lowerLimit":"15.2","upperLimit":"25.2","value":"24.6"},{"comment":"Insufficient timepoints to calculate this data.","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"C1D15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"65"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"description":"Elimination half-life of RMC-4630 and cobimetinib or RMC-4630 and osimertinib","dispersionType":"Full Range","groups":[{"description":"Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.","id":"OG000","title":"Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)"},{"description":"Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.","id":"OG001","title":"Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.","id":"OG002","title":"Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.","id":"OG003","title":"Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.","id":"OG004","title":"Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.","id":"OG005","title":"Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2"},{"description":"Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.","id":"OG006","title":"Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.","id":"OG007","title":"Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15","title":"t1/2","type":"SECONDARY","unitOfMeasure":"h"}